The burgeoning landscape of medication for obesity and type 2 glucose intolerance is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and https://murraycasa187013.livebloggs.com/45540475/retatrutide-vs-tirzepatide-a-comparative-analysis